2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.24 Prognostic Value of Functional Subtype Classification of Co-Occurring TP53 Mutations in Patients with EGFR-Mutant NSCLC Treated with TKI

EP.12A.24 Prognostic Value of Functional Subtype Classification of Co-Occurring TP53 Mutations in Patients with EGFR-Mutant NSCLC Treated with TKI

Back to course

Pdf Summary

The study examines the prognostic significance of TP53 mutation subtypes in non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (TKIs). Previous evidence suggests co-occurring TP53 mutations in EGFR-mutant NSCLC are linked with poorer clinical outcomes, such as reduced progression-free survival (PFS) and overall survival (OS). This research seeks to refine therapeutic strategies by assessing the prognostic value of functional classifications of these TP53 mutations.<br /><br />A retrospective analysis was conducted on patients diagnosed with sensitive EGFR mutation-positive NSCLC and treated with first- or second-generation TKIs from 2013 to 2017. Patient data collected included demographics, treatment specifics, and molecular characteristics focusing on EGFR and TP53 mutation status. TP53 mutations were categorized as pathogenic or non-pathogenic/unknown. The study employed statistical tests, including chi-square, one-way ANOVA, and Kaplan-Meier curves to compare treatment response rates and PFS between TP53 mutant and wild-type cohorts, and among subgroups with pathogenic TP53 mutations.<br /><br />Results showed that TP53 mutation-positive patients (31 individuals, median age 61.6) were generally younger than those with wild-type TP53 (42 individuals, median age 72), with age being statistically significant (p=0.003669). While there were numerical differences in treatment response and PFS between TP53 mutant and wild-type groups, these were not statistically significant. However, patients with pathogenic TP53 mutations had a substantially lower PFS (8.9 months) compared to TP53 wild-type patients (11.6 months), with this difference being statistically significant (p=0.0057).<br /><br />The conclusion highlights that pathogenic TP53 mutations could be an important prognostic marker for shorter PFS in EGFR-mutant NSCLC patients treated with TKIs. This finding emphasizes the necessity for personalized treatment methods and further research to enhance outcomes for this patient group, particularly those with concurrent TP53 mutations.

Asset Subtitle

Divya Chukkalore

Meta Tag

Speaker Divya Chukkalore

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

TP53 mutation

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR mutations

tyrosine kinase inhibitors

TKIs

progression-free survival

prognostic significance

personalized treatment